Blood transfusion is an indispensable cell therapy. Red blood cell (RBC) transfusion
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developing regions of the world, research on the in vitro expansion of the supply of RBCs as an alternative transfu sion product has gained new momentum.
Sporadic blood shortages can occur in association with natural or anthropogenic disasters. In emergencies, national plans call for sponsoring emergency blood drives and sharing blood resources across geographic areas, but the infrastruc ture required to maintain blood collection and distribution systems may be disrupted during severe disasters, such as the 2008 Sichuan earthquake in China and the 2011 Tohoku earthquake and tsunami in Japan. In addition, blood short ages related to holidays are common; there are fewer donors in Beijing in winter and summer, when students, who con stitute most of the donor population, have returned to their homes (Yu et al. 2010) .
Although the overall blood supply in industrialized coun tries is adequate, finding blood for certain patients can still be difficult. Because of the substantial polymorphism of blood group antigens, chronic shortages of blood for alloimmunized patients and for some patient groups with rare blood types can occur even in developed countries (Zimring et al. 2011) . Providing blood for chronically transfused patients and patients with rare blood types is an additional challenge because of the risks of alloimmu nization, which is a complex immune reaction resulting in the development of antibodies against antigens present on B lood cell transfusion is a mainstay of modern medicine and an irreplaceable cell therapy under certain condi tions, from red blood cell (RBC) and platelet transfusions to bone marrow transplantation (Timmins and Nielsen 2009 , Migliaccio AR et al. 2012a , Zeuner et al. 2012 . The need for blood is widespread, but there is a major imbal ance between the demand for and the supply of donors. The safety and adequacy of the blood supply are national and inter national priorities (Migliaccio AR et al. 2012a) . Around 92 million blood donations are collected annually and dis tributed worldwide from all types of blood donors (voluntary, family, replacement, paid; WHO 2012) . Approximately half of these donations are collected in highincome countries, which represent approximately 15% of the world's popula tion (WHO 2012) . The blood supply in developed countries therefore appears to be largely adequate. In 2008, the data on the number of units collected and blood use from the United States indicated that the number of screened allo geneic blood donations that passed all tests exceeded the total number of units transfused by 13% (Migliaccio AR et al. 2012a ). The World Health Organization, however, indicated that supply constraints were a matter of particular concern in developing countries; only 39% of worldwide blood donations are collected in these regions, which are home to about 82% of the world's population (for a review, see Timmins and Nielsen 2009) . Against this backdrop, in
RBCs. This phenomenon is more common when donors and recipients belong to different ethnic groups (Ameen et al. 2003 , Thompson et al. 2011 , Zimring et al. 2011 . Rhesus negative blood is so rare in the Chinese population that it is referred to as "panda blood." Although it occurs in 15% of nonChinese people, it is found in only 0.3% of people of Chinese Han ancestry (Yu et al. 2010) . Incompatible transfusions may occur when antibodies become undetect able. Because of this low but consistent risk, alloimmunized patients are transfused with blood from matched donors identified by targeted recruitment programs. Despite these efforts, blood for alloimmunized patients is often unavail able. These considerations underscore the importance of developing alternative transfusion products.
Although testing and policy decisions have combined to make blood supplies in many countries among the safest in the world, some risk of transfusiontransmitted infections with bloodborne diseases (e.g., HIV [human immuno deficiency virus], hepatitis, syphilis) still exist, and 5%-10% of HIV infections worldwide are caused by transfusion of contaminated blood or blood products (for a review, see Yu et al. 2010) . In China, 69,000 of those infected with HIV/AIDS (acquired immunodeficiency syndrome) con tracted the disease through transfusion or illegal blood donations made using contaminated equipment, which accounts for 10.6% of all HIV infections in China (about 650,000 in late 2005; Yu et al. 2010 ). In addition, the growth in blood transfusions to support advanced surgical pro cedures and medical treatments in the increasing elderly population (those older than 60 years old) is expected to lead to an inadequate blood supply, even in developed coun tries, by 2050 (for a review, see Migliaccio AR et al. 2012a) .
In response to these concerns, the ex vivo expansion of human erythroid cells from hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) derived from cord or adult blood or from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) has been proposed as a means of ensuring an adequate and safe supply of RBC transfusion products (figure 1a). Recent scientific and technical discoveries focused on maximizing the numerical expansion of RBCs in a laboratory setting have given new momentum to the concept of manufactur ing RBCs in the large numbers required for transfusions. It is now possible, at least in theory, to produce several transfusion units of RBC products from a single cordblood donation. In this article, we summarize the recent advances in ex vivo production of RBCs from various cell sources for transfusion purposes and discuss the remaining scientific and logistic hurdles to be overcome before this technology can be translated into the clinical arena in this rapidly devel oping field.
RBCs:
Can we master such a refined cellular model in Petri dishes? Perhaps the most obvious goal for ex vivo manufacture of mature blood cell products is the production of RBCs. At first sight, RBCs seem to be composed of simple bags that have lost their vital elements, including the nucleus. In fact, they are cells that have pushed their specialization, such as oxygen transport, to the point of eliminating all the non useful elements. Ongoing research is intended to create arti ficial blood that could be given to any recipient. Mammalian erythropoiesis constitutes the entire process by which HSCs in the bone marrow progress through several precursor stages into mature RBCs. This process includes the dif ferentiation of early erythroid progenitors (burstforming units [BFU]-erythroid) through late erythroid progenitors (colonyforming units [CFU]-erythroid) and, finally, mor phologically recognizable erythroid precursors (Elliott et al. 2008) . RBC transfusion is currently dependent entirely on the availability of donor material, which has led to supply constraints and safety concerns. However, if it is not possible to replace nature, why not simply copy it?
Methods for cultivating small amounts of lineage committed blood progenitor cells have been known for almost two decades (Peschle et al. 1993) . We have sufficient know ledge of the biology of HSCs to make the production of RBCs in the laboratory a realistic prospect. Recent studies have described the production and detailed characteriza tion of RBCs produced in laboratory cultures. Currently, the ex vivo largescale generation of human RBCs involves a threestep process: optimization of progenitors, expansion of erythroid progenitors, and terminal maturation ). First, cultures are stimulated with growth factors, including stem cell factor, FMSlike tyrosine kinase receptor 3ligand, and thrombopoietin, which contribute to the proliferation of HSCs and their immediate progeny. Second, cultures are stimulated with other growth factors, including interleukin3, stem cell factor, and erythropoietin, plus dexamethasone (a glucocorticoid receptor agonist) and estradiol, either alone or in combination, which promote the expansion of erythroid progenitor cells by blocking maturation and activating telomerase activity, also known as phase 2. Ex vivo-expanded erythroblasts are transferred into maturation cultures, also referred to as phase 3, and stimulated with erythropoietin and insulinlike growth factor 1. Under these conditions, erythroblasts progress to the orthochromatic stage (Chen L et al. 2007 , Stellacci et al. 2009 ). Enucleation remains inefficient and must be cocultured on a layer of either murine bone marrow stromal cells (MS5; Giarratana et al. 2005 , Miharada et al. 2006 or human mesenchymal stromal feeder cells, which probably exert in vitro the same functions performed by macrophages in vivo (Chasis and Mohandas 2008) -that is, providing physical support or facilitating iron uptake (Isern et al. 2008 , Leimberg et al. 2008 ). This culture system offers a new approach to achieve up to a 2millionfold numerical expansion of enucleated erythrocytes that display charac teristics similar to those of native RBCs in terms of mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration (Chang KH et al. 2011 ). However, given that the ultimate goal of ex vivo
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cell source is dependent on donations and would require dedicated blood banks (for a review, see Anstee et al. 2012) . Meanwhile, collection and testing are associated with sub stantial costs, and the risks associated with donated blood products remain. As for many other therapeutic applica tions, the production of RBCs from pluripotent stem cells (PSCs), whether those are hESCs or iPSCs, is of inter est. PSCs could provide a limitless cell source, free of the constraints of obtaining supplies. In this respect, PSCs are promising candidates for the ex vivo generation of RBCs, just as they are candidates for use in other fields of production of RBCs is their clinical application, the use of feeder cells should be avoided. In an attempt to simplify the culture process, RBCs were therefore generated from adult peripheral blood stem cells, without the need for stromal cells or macrophages, both of which are involved in nor mal erythropoiesis. This culture system, without the use of stromal cells or macrophages, greatly facilitates the devel opment of a manufacturing process suitable for providing RBCs for clinical use.
Although cord blood represents a more accessible and proliferative source of HSCs than adult blood does, this Overview Articles regenerative medicine (Arora and Daley 2012, Migliaccio AR et al. 2012a) . In a large number of studies, it has now been reported that hESC cultures can be induced to undergo hematopoietic differentiation that leads to the generation of nucleated erythroblasts, synthesizing a mixture of embry onic and fetal hemoglobin. A critical scientific and clini cal issue is whether hESCderived erythroid cells can be matured ex vivo to generate enucleated RBCs (Miharada et al. 2006 , Hiroyama et al. 2008 . Two different approaches have been used, either alone or in combination, to induce the initial stages of differentiation: by recourse to coculture on feeder stromal cells or by formation of embryoid bodies. More recently, Lu and colleagues (2008) produced enucle ated erythrocytes with hemangioblasts from hESCs by a divergent process; however, these erythrocytes synthesized fetal and embryonic but not adult chains of hemoglobin. Tellingly, the terminal maturation of the cells depended on the culture conditions: The hemangioblasts cultured in feederfree conditions showed 10%-30% enucleation, whereas those cultured on mesenchymal stem cells showed approximately 30% enucleation, and the enucleation process was further enhanced by the use of murine OP9 stromal cell layers (Lu et al. 2008 ). In addition, in a previous study, Ma and colleagues (2008) combined embryoidbody forma tion, which phenotypically and genetically mimics human early yolk sac hematopoiesis, with stromal coculture and demonstrated that hESCs that were first allowed to form embryoid bodies and then subsequently plated onto mouse fetal liverderived stromal cells generated a large quantity of hematopoietic progenitors that could give rise to RBCs, providing a means to characterize hESCderived erythro poiesis. Interestingly, tracing differentiation at a clonal level demonstrated that globin expression in the erythroid cells changed in a timedependent manner: Embryonic εglobin expressing erythroid cells from individual clones decreased from around 100% to around 50%, whereas adult βglobin expressing cells increased to around 100% in all of the clones examined (Ma et al. 2008) . iPSCs possess the characteristics of hESCs (for a review, see Han et al. 2010) . They are capable of selfrenewal and differentiation into all cell types of the three germ layers in vitro, and there are several methods for generating RBCs from iPSCs (Choi et al. 2009a , 2009b , Lengerke et al. 2009 ). Szabo and colleagues (2010) recently showed that human fibroblasts transfected with octamer binding transcription factor 4 could be directly converted to HSClike CD45 + cells undergoing incomplete reprogram ming. This manipulation affects the transition from primi tive to definitive hematopoiesis.
Current technologies are able to generate sufficient RBCs for their functional evaluation in vivo. However, before this artificial blood can be used clinically, the RBCs generated ex vivo must be shown to be functionally equivalent to donor derived RBCs. The functionality of cultured RBCs once injected into the bloodstream was first proved by Hiroyama and colleagues (2008) and Miharada and colleagues (2006) , who demonstrated that transfusion of ex vivo-produced RBCs obtained from an immortalized embryonic stem cell line could protect mice from lethal hemolytic anemia in a model of transfusion. There is proof of the principle that injected chromium51labeled RBCs generated auto logously under good manufacturing practice conditions from mobilized CD34 + cells obtained from an adult volun teer by apheresis (the only method accepted by the US Food and Drug Administration) survived in vivo in humans as long as their definitive adult counterparts (Giarratana et al. 2011) . This study was received with both excitement and reservations by the hematological community. On one hand, these data provide clear evidence of the feasibility and safety of deriving functional RBCs for clinical use through labora tory culture. On the other hand, the holy grail of therapeutic transfusion is still unrealistic on the basis of the protocol described above. Several hurdles remain to be overcome before effective clinical trials of stemcellderived RBCs can be performed.
Current barriers to clinical translation
The next decade represents an attractive opportunity for the translation of PSCderived ex vivo-produced RBCs into clinical practice for transfusion. However, a number of difficulties and constraints remain. The proposal of an alternative to conventional transfusion includes scientific, technological, social, and public heath barriers, all of which will be involved in determining the success with which this innovative idea will be translated into clinical practice.
RBCs generated ex vivo:
What is the best cell source? Although the manufacture of sufficient RBCs for transfu sion will need to address the specific needs of transfusion medicine, one of the most important aspects of RBC expan sion ex vivo involves the identification of the optimum source of the starting material. The idea of artificial blood for transfusion purposes became realistic when the potential for using currently discarded material with unlimited avail ability to generate sufficient RBCs was realized (Migliaccio AR et al. 2012a) . It is now at least theoretically possible to attain the quantitative goals of RBC production for clinical transfusion from a single cordblood donation , Peyrard et al. 2011 . Unfortunately, however, low volumes of cord blood are presently stored, and their blood group phenotypes are unknown. Intrinsic differences in HSC content and in the proliferative abilities of HPCs mean that this cell source is dependent on donations and would require the establishment of dedicated blood banks ). However, cordblood banks for HSC transplantation have been established worldwide in the infrastructure of blood transfusion services to facilitate the collection of cord blood, and much effort is currently being invested in developing strategies for expanding the number of HPCs in cordblood donations to elicit more effi cient and rapid posttransplant engraftment of neutrophils and platelets. The expansion potential of peripheral blood
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stem cells is considered to be lower than that of cord blood, hESCs, and iPSCs, and consequently, they are not favored starting materials for those who wish to use the large scale production of RBCs for therapy. However, peripheral blood mononuclear cells are more readily obtained as a byproduct of leukoreduction and a waste product of blood donation, and they can be cultured to produce functional RBCs (Anstee et al. 2012) . Theoretically, peripheral blood mononuclear cells from each wholeblood donation could produce one or more units of RBCs, and therapeutic doses of RBCs for selected indications could thus be achieved much sooner than from other stem cell sources from which adult phenotypes have not yet been generated (for a review, see Anstee et al. 2012) . Overall, these data indicate the exis tence of a potentially vast but untapped resource for the ex vivo generation of RBCs. However, the risks associated with donated blood products remain. Understanding the underlying variability in the numbers of RBCs generated from cultures from different donors will help optimize donor selection and represents an important facet of the ex vivo production of transfusion products from different starting materials.
Although cord blood provides a much more attrac tive source of stem cells for culture than adult blood does because of the much greater proliferative capacity, the potential of stem cell sources for the in vitro generation of RBCs has yet to be fully characterized. Given that a rare phenotype product would require a matching rare phenotype cordblood donation as a starting material, such yields are clearly insufficient. In principle, the ideal starting cells for the manufacture of RBCs for routine clinical use would have unlimited expansion potential to justify the costs associated with their characterization for a production process able to meet current good manufacturing practice criteria for medicinal products (Douay et al. 2009 ). As with many other therapeutic applications, hESCs and, more recently, iPSCs, which could provide essentially limitless and well characterized supplies of starting materials, have been investigated as potential sources for the generation of pheno typically matched RBCs (Chang KH et al. 2011 ). Many studies have established methods for generating mature RBCs from hESCs and have extensively character ized the biologic properties of these RBCs derived from hESCs. In terms of RBCs, hESCs have been proposed as a scalable source of stem cells for the production of O Rhesus negative RBC transfusion products ex vivo. However, there are a number of important challenges. For instance, the genotype of the hESC cell lines currently available (H1, H7, and H9) for expansion to produce RBCs under conditions suitable for good manufacturing practice production is O or A Rhesus positive, and they are therefore not suit able for generating universal donor RBCs (for a review, see Migliaccio AR et al. 2012a) . Ongoing efforts are needed to identify additional hESC lines with the potential to generate O Rhesusnegative RBCs. Determining the hESC lines suit able for the production of RBCs for patients with rare blood types presents more challenges. Theoretically, this could be remedied by engineering rare blood-specific hESC lines using a homologous recombinationbased approach (Zou et al. 2011) . However, the genetic basis of some blood group polymorphisms (e.g., Rhesus) is still not completely under stood. Therefore, further studies on hESC biology and on the genetic basis of RBC antigen heterogeneity would be needed in order to manufacture blood group-specific hESC lines. Unfortunately, hESCs pose ethical problems regarding their cell origin. iPSCs, in contrast, can be obtained from any donor, and their generation from a chosen donor with the required universal donor blood type, including the minor blood group antigens, suggests that they may eventually prove to be the best source of clinically useful RBCs. However, both hESC and iPSCderived erythroid progenitors have low proliferation rates compared with cells derived from cord blood and produce suboptimal levels of enucleated RBCs. It has been calculated that HSCs derived from PSCs (500 erythroblasts per hESC or iPSC) have poor erythroid expan sion potential compared with cordbloodderived CD34 + cells (10 4 -10 5 erythroblasts per CD34 + cell) (for a review, see Migliaccio AR et al. 2012a ). The production of RBC therapy products for transfusion from PSCs requires enor mous amplification of the PSCs themselves. However, despite these limitations, iPSCs may be an attractive stem cell source for the production of RBCs for transfusion in alloimmunized patients. Notably, PSCderived RBCs express mostly embryonic and fetal hemoglobin and relatively little adult hemoglobin (Qiu et al. 2008) . Fetal hemoglobin has a greater affinity for oxygen than does adult hemoglobin. RBCs expressing fetal hemoglobin are slightly less efficient than those expressing adult hemoglobin in terms of oxygen delivery, although patients who retain fetal hemoglobin expression into adult life are largely asymptomatic, and the persistence of fetal hemoglobin may alleviate hemoglobin disorders such as sickle cell anemia, because the residual fetal γglobin chains can substitute functionally for the mutated βchains (Manca and Masala 2008) . Indeed, the reactivation of fetal hemoglobin is being investigated as a therapeutic target in hemoglobin disorders (Olivieri and Weatherall 1998) , which suggests that the fetal rather than adult pheno type RBCs derived from iPSCs from patients with hemoglo binopathies are not necessarily a barrier to iPSCs' use as an autologous transfusion product.
Regarding the ultimate objective of cell therapy, the cur rent techniques for obtaining iPSCderived therapeutic products are cumbersome, lack definitive procedures for quality control, carry an undefined risk of tumorization and of transmission of pathogens, and require the imple mentation of specific regulatory frameworks (Mazurier et al. 2011) . A series of approaches have been explored to ensure the safety of iPSCs, but these methods have often been associated with less than efficient cell reprogramming, which remains a major problem. A balance has yet to be struck among the amplification potential, genetic stability, and tumorigenicity of the cells. Dias and colleagues (2011) , who used the OP9 coculture system, followed by dissociation and reaggregation on low attachment plates with the addition of cytokines, and then coculture on MS5 feeder cells to induce maturation. Up to 2 × 10 5 RBCs could be generated from one initial hESC, and a similar level of expansion was also obtained with iPSCs. Although this was preferable to the results of previous practices, the need for murine cells for coculture throughout the differentiation procedure remains a drawback for potential clinical applica tions. Compared with the therapeutic quantities of RBCs, recent studies involving common static cultivation methods using flasks, dishes, or gaspermeable bags have shown little significant progress in producing RBCs from PSCs more cost effectively (Migliaccio AR et al. 2012b) . One major technical limitation is that RBCs generated using static cultures on a laboratory scale do not proliferate at concentrations greater than 10 6 cells per milliliter (Migliaccio AR et al. 2012a ). To reduce the inhibitory effects exerted by the negative regula tory factors released by erythroblasts as they mature, cell interactions need to be minimized ex vivo by maintaining the cell density at fewer than 10 6 cells per milliliter. Production of 2.5 × 10 12 RBCs would therefore require at least 2500 liters of culture medium (for a review, see Migliaccio AR et al. 2012a) . In all methods published to date, cultures were grown in static tissue flasks, and the actual culture volumes and cell yields were small. However, even assuming that enucleated RBCs could be generated from PSCs with a yield equivalent to that of primitive erythroblasts, the production of a single unit of RBCs would require 500 square meters of culture area, or approximately 28,575 T175 tissue culture flasks (Timmins and Nielsen 2011) . Using currently avail able methods, the task of replacing donorderived erythro cytes with in vitro-generated RBCs will be impractical, given that current methodologies to generate RBCs ex vivo are extremely inefficient and clearly unsuitable for the manu facture of clinically meaningful quantities. The production of a large number of RBCs therefore requires revolutionary advances in areas such as the formulation of humanized cul ture media using clinicalgrade reagents, the development of appropriate bioreactor technologies, and overcoming barri ers to cell derivation (figure 1b).
Cultivation of RBCs: Production costs are prohibitive today… but tomorrow? Heavy supplementation with growth factors and other reagents increases the cost of culture media, which may present a significant barrier to the routine manu facture of RBC products. Compared with the current RBC transfusion products generated from iPSCs, the prob lem is different (for a review, see Mazurier et al. 2011) . In principle, ex vivo-generated erythroblasts could also be used as transfusion products, although there is an oncogenic risk associated with insertional mutations in the transfusion of nucleated cells. However, the safety concern over the poten tial genomic instability of these stem cells is reduced because RBCs, as the final transfusion product, are enucleated and easily purified by simple filtration or irradiation.
Ex vivo expansion of RBCs: An oasis in the desert, or rivers of blood? Prominent researchers worldwide have been investigating ways to develop RBCs in vitro using static cultures on a laboratory scale, but it is clear that scaling up from the few billion RBCs generated in a Petri dish to the industrial level of production required for a therapeutic dose will require more efficient processes (Timmins and Nielsen 2009, Migliaccio AR et al. 2012a ). Cultured RBCs for clinical applications must be produced in concentrations compa rable to that of a standard RBC concentrate transfusion (i.e., 2.5 × 10 12 ; Zeuner et al. 2012) . Generating enough RBCs ex vivo for transfusion medicine probably represents the primary technical challenge.
The authors of several studies have claimed that their respective protocols resulted in the largescale generation of RBCs from iPSCs, which is a prerequisite for any poten tial clinical usage (Chang KH et al. 2011) . However, this is only the tip of the iceberg; unlike HSCs from cord blood, the efficacy of iPSCs in terms of RBC production remains extremely low, even though iPSCs may be regarded as a potentially unlimited source of RBCs. Prolonged coculture of hESCs and human telomerase reverse transcriptase gene transduced human fetal liver hepatocyte cells allowed Qiu and colleagues (2008) to obtain approximately 80 erythroid cells per hESC, compared with an estimated 5 × 10 4 -fold expansion achieved by a single CD34 + cell in coculture. Using the H1-mouse fetal liverderived stromal cell cocul ture system, Ma and colleagues (2008) demonstrated that hESCs that were initially allowed to form embryoid bodies before plating onto mouse fetal liverderived stromal cells generated large erythroid bursts consisting of approxi mately 2 × 10 5 erythroid cells collected from one hESC derived erythroid burst. Taking into consideration the CFU frequencies and further expansion potentials in liquid culture, 10 4 hESCs can be amplified to approximately 10 6 mature RBCs. In addition, a slightly higher production efficiency can be achieved by embryoidbody formation, disaggregation, and replating following the liquid culture protocol for erythroblastic differentiation or maturation, supplemented with human plasma and an evolving cocktail of cytokines based on stem cell factor, interleukin3, and erythropoietin (Lapillonne et al. 2010 (Giarratana et al. 2011) . Consequently, it has been proposed that RBCs manufactured in vitro from stem cells could provide a limitless source for transfusion purposes. However, the high hope for this proposal must be tempered by the cold light of reality. What future strate gies are needed in order to produce an appropriate product at an acceptable cost, and how far are we away from this scenario?
The ex vivo generation or production of RBCs on a scale large enough for clinical use is currently an unrealistic and expensive proposition, even in industrialized countries. Ongoing efforts provide cause for optimism and suggest that this ambitious goal is achievable. However, the sub sequent manufacture of clinically meaningful quantities of RBCs, which is probably the primary technical obstacle to overcome in order to make the transfusion of cultured RBCs a reality, will require revolutionary advances in pro cess engineering. Among the published methods for RBC generation ex vivo, the growth factors used to stimulate the culture, including stem cell factor, erythropoietin, and glucocorticoids, play interrelated roles in regulating eryth roblast expansion , Mountford et al. 2010 ). Clearly, their concentrations and the tempo rospatial administration required to obtain optimal expan sion remain to be determined. Further studies are needed in order to understand which molecular characteristics of the signaling pathways activated during erythroid differentia tion may indicate novel approaches to promote erythroblast expansion. Knowledge of the signaling pathways control ling HSC behavior has resulted in the identification of soluble small molecules of defined chemical composition as substitutes for crude biologics (Sato et al. 2004 , Chen S et al. 2006 . In view of these promising future applications, the procedures used to derive RBCs from PSCs urgently need to be optimized in order to achieve clinical standards. Nevertheless, even with optimized experimental procedures, the largescale production of RBCs directly from PSCs will be a costly and timeconsuming process. How can we improve it? A number of strategies might eventually be combined to address this question.
One possible solution would be to generate erythroid progenitor cell lines from PSCs by genetic or epigenetic treatment, and these erythroid progenitor cell lines could then differentiate into mature RBCs (Hiroyama et al. 2008 ). The transition from PSCs to erythroid progenitor cell lines is associated with extensive chromatin remodeling that ensures activation of erythroidspecific genes. Epigenetic modifications, which involve modifications to DNA (e.g., DNA methylation) or modifications to histone proteins at specific amino acid residues (e.g., the acetylation or deacety lation of specific histones that relax or condense chromatin), and chromatin remodeling, have traditionally been thought cost-approximately $223.09 per unit of donor RBCsproducts manufactured using current medium formulations can clearly not compete (USDHHS et al. 2011) . The scale of any such process could be compared with a produc tion process for recombinant proteins and monoclonal antibodies. Here, a 2500liter fedbatch process operating at a maximum stirredtankreactor density of 5 × 10 7 cells per milliliter with a yield of 10 grams of monoclonal anti bodies per liter can produce 25 kilograms of monoclonal antibodies. Cultivation of RBCs in the same system would yield 62.5 transfusion units with a current value of only $13,943 ($223.09 per unit), which would fail to cover even medium costs using current formulations (USDHHS et al. 2011) . On the basis of a conservative estimate, to produce a single unit of RBCs using current formulations would cost $8330, assuming a simplebatch or fedbatchtype process at a final cell density of 5 × 10 7 cells per milliliter (Timmins and Nielsen 2009) .
In order for cultured RBCs to become routine, significant advancements are required at both the biologic and the engineering levels. Substantial improvements in numerical expansion using lowcost media will be necessary to address even a fraction of the current demand, and technological breakthroughs are needed to overcome the engineering challenges associated with physically manufacturing such vast numbers of cells. Revealingly, the removal of albumin and transferrin from cell culture media is a task that has already been successfully undertaken in the biopharma ceutical industry (for a review, see Timmins and Nielsen 2009) . Similar strategies are likely to be applicable in the context of RBC manufacture, with lowcost reagents serving as a replacement. The use of peptide mimetics or small mol ecules in place of recombinant proteins could significantly reduce media costs. Although they are biologically com plex in their mode of action, erythropoietin, interleukin3, stem cell factor, and insulin can potentially be replaced by smallmolecule mimetics (Air et al. 2002 , Perugini et al. 2009 ). Although peptide mimetics of erythropoietin, throm bopoietin, and insulin have already been described and can typically be produced at a fraction of the cost of recombi nant proteins, which could lead to substantial savings, the development of sufficiently lowcost media will remain challenging. In a more general context, careful optimization of nutrient and growth factor concentrations would be an essential aspect of minimizing processing volumes while maximizing cell yields. It is possible that the notion of high cost may be viewed differently in the event of a shortage of supplies caused by a lack of available donors. Therefore, in the medium and long term, cultured RBCs may represent a means of satisfying clinical requirements.
Ex vivo expansion of RBCs: How can we improve it?
Despite delays in their eventual application, the clinical use of cultured RBCs from stem cells is already possible if suf ficient cells can be generated at an acceptable cost. Although many daunting challenges need to be overcome before the clinical use of the final enucleated RBC product. In addition to microRNAs, another class of noncoding RNA-long non coding RNAs (lncRNAs)-has recently been shown to be crucial in important biological processes, including stem cell pluripotency, morphogenesis, and development (Li X et al. 2013 ). Hu and colleagues (2011) reported the discovery of long intergenic noncoding RNA erythroid prosurvival (lincRNAEPS), a murine lncRNA that is strongly induced when erythroid precursors begin to synthesize hemoglo bin and other lineagespecific proteins and that facilitate erythropoiesis by suppressing apoptosis. Careful followup studies have demonstrated that lincRNAEPS mediates this effect at least partly by suppressing the expression of the apoptosisassociated specklike protein PYCARD, a signal ing molecule that promotes cell death through activating caspases (Ohtsuka et al. 2004) . Of note, genetic manipula tion of lincRNAEPS expression did not alter erythroid dif ferentiation, which suggests that its biological activities may be limited to influencing the apoptotic pathway. It is worth noting that lincRNAEPS is expressed minimally in other hematopoietic lineages, which indicates erythroidspecific cells. It will therefore be interesting to investigate this new facet of erythroid development and to extend the scope of known lncRNA actions. It is possible that pharmacologic inhibition of proapoptotic signaling pathways could be useful for ex vivo production of RBCs. In this regard, the lincRNAEPS-PYCARD axis could represent a "druggable" pathway (for a review, see Paralkar and Weiss 2011). It will be important to assess how manipulated lincRNAEPS and PYCARD affect erythropoiesis during ex vivo production of RBCs as a transfusion product.
The scientific basis for generating safer and better prod ucts for clinical use by donor screening and product testing has made transfusion safer. However, as a result, transfusion related alloimmunization resulting in the development of antibodies against antigens present on RBCs, which may express antigens from 30 blood group systems represent ing over 300 different antigens, has emerged as a major clinical issue (Engelfriet et al. 2006 , Poole and Daniels 2007 , Anstee 2009 , Daniels and Reid 2010 . These antibodies may have serious consequences, such as hemolysis, organ failure, and even death, if the patient is transfused with RBCs expressing cognate antigens. Beyond the ABO blood group system, some blood phenotypes characterized by either the absence of a highfrequency blood group anti gen (a public antigen) or the presence of a lowfrequency antigen (a private antigen) are clinically significant (for a review, see Bagnis et al. 2009 ). The ability to generate RBCs of a chosen blood group phenotype would represent a major advance in transfusion when considering low and high frequency blood group antigens. Erythrocytes minimally express human leukocyte antigen molecules, and transfusion of group O, Rhesusnegative, Kellnegative blood would be compatible with the majority of recipients . The ultimate aim would be to produce a universal RBC supply that could be used regardless of the recipient's to contribute to celltypespecific gene expression patterns. Once the chromatin configuration is established, methyla tion of specific DNA regions ensures that the chromatin remodeling is inherited by the cellular progeny. These plastic processes are regulated by families of enzymes called methylases, histone acetyltransferases, and histone deacetylases (Wozniak and Bresnick 2008) . Recent insights into the events that drive terminal erythroid maturation have demonstrated that histone deacetylases are required for chromatin condensation and enucleation in mouse fetal liver erythroblasts. Administration of histone deacetylase inhibitors to human erythroid precursors cultured from CD34 + cells inhibited terminal differentiation. HDAC2 is probably the most important type of histone deacetylase for erythropoiesis, because either specific pharmacologic inhibi tion or small hairpin RNA-mediated HDAC2 knockdown blocked chromatin condensation and enucleation of mouse fetal liver erythroblasts in vitro (Ji et al. 2010) . Revealingly, the fact that glucocorticoids are strong inhibitors of HDAC2 may explain the poor enucleation efficiency of human erythroblasts generated in phase 2 cultures (Li LB et al. 2010) . It is therefore conceivable that nuclear condensation and enucleation of erythroid cells generated in the presence of glucocorticoids might be improved by adding histone deacetylase activators in phase 3 cultures.
Another interesting possibility involves the use of genetic manipulation to improve erythroid commitment and amplification. This could involve screening for the genes involved in amplification and modifying the erythroid pro genitors in accordance with the results, with overexpression or constitutive or conditional expression of a gene favoring amplification and suppression of inhibitory genes. Notably, microRNAs are a class of recently identified small regulatory RNAs that downregulate the expression of their target genes by degrading the target messenger RNA, blocking transla tion, or both (Bartel 2009 , Guo et al. 2010 . Hematopoiesis is a multistep process that leads to the production of mature blood cells and is controlled by many factors, including microRNAs. Interestingly, specific microRNAs are impor tant regulators of several aspects of erythropoiesis, includ ing erythroid lineage determination, erythroid progenitor proliferation, terminal erythroid differentiation, and enu cleation (for a review, see Hattangadi et al. 2011) . It is therefore reasonable to speculate that the genetic manipula tion of cultured erythroid cells by different combinations of microRNAs might allow the generation of higher numbers of mature RBCs ex vivo. Consistent with this, an immor talized erythroid progenitor cell line derived from human iPSCs was first transformed with the transcription factor stem cell leukemia/Tcell acute lymphoblastic leukemia 1 (which plays essential roles in early hematopoiesis and dif ferentiation of erythroid cells and megakaryocytes) in order to boost the rate of production of hematopoietic cells, espe cially RBCs (Kurita et al. 2013) . Unlike the manipulation of the other cells of the body, genetic manipulation of cul tured erythroid cells is unlikely to represent a barrier to the Overview Articles Overview Articles composition, which makes it difficult to directly compare the different reported procedures. It is worth noting that CD34 + cells were seeded onto fibronectinconjugated 3D polyethylene terephthalate scaffolds or aminated nanofiber scaffolds with ethylene and butylene spacers and cultured in the absence of stromal cells and serumfree medium with cytokines for 10 days (Feng et al. 2006 , Chua et al. 2007 ). This technique generated up to 50 times more CD34 + cells than are generated in a standard static twodimensional (2D) cul ture. Using a strategy to reconstitute both HSC and stromal cell components of the HSC niche, CFUs were maintained for 14-28 days on polyurethane foam, porous polyvinyl fluoride resin, or polyester nonwoven discs, and the results were better than those from conventional suspension cul ture (Chua et al. 2007 , Jozaki et al. 2010 , Miyoshi et al. 2011 , MorteraBlanco et al. 2011 . On the basis of a perfusion system for cell seeding and culture through the pores of 3D scaffolds, starting from minimally processed bone marrow aspirates and avoiding 2D culture expansion, CFUs increased by more than 90 times over 19 days, compared with 2D culture (Braccini et al. 2005) . Interestingly, a 3D scaffold of collagen gel with supporting mesenchymal stem cells expanded HSCs or HPCs in two sites: highly proliferative and differentiating cells in suspension above the collagen gel and proliferative but primitive HPCs within the collagen fibers, which suggests that this paralleled the hematopoietic microenvironment, wherein collagen containing mesenchy mal stem cells mimic the endosteal region and enable HPC expansion. Longterm maintenance and expansion of HSCs or HPCs has been demonstrated in nonwoven polyethylene terephthalate fiber matrices with defined microstructures for 7-9 weeks and in natural cancellous bone as scaffold with osteoblasts as supporting cells for 5 weeks (Li Y et al. 2001 , Tan et al. 2010 . In all of these studies, the retention of stemness was examined in HSCs within the scaffold, but whether the resident stem cells could simultaneously self renew and generate progeny of different lineages on a large scale was not assessed. Although more research is required, current progress in 3D scaffolds has shed new light on the continuous ex vivo expansion of RBCs by replicating the in vivo environment of the bone marrow niche.
In the future, cell biologists will need to work with bio material scientists to assess the ability of 3D matrix scaf folds to mimic the hematopoietic niche and support not only HSC or HPC expansion and proliferation but also the retention of HSCs capable of longterm differentiation to generate progeny. We envisage the possibility that, in the near future, 3D scaffolds may be used to produce HSCs or other rare pluripotent or multipotent cell types ex vivo, thus providing for the first time an unlimited source of rare adult stem cells for regenerative medicine practices. Meanwhile, 3D scaffolds also provide a supportive platform and mimic the bone marrow microenvironment, which enables the expansion and maintenance of an HSC supply and RBC production. In addition, even if experiments with 3D scaf folds are becoming more common, not only are structural ABO blood group phenotype. Against this backdrop, an ex vivo strategy to generate control blood samples with a chosen phenotype different from that of the original donor would be an important advance for antibody detection and identification in transfusion medicine. Recently, in an exciting study, Bagnis and colleagues (2009) revealed a genetic strategy that could provide powerful new tools to generate a chosen blood group phenotype different from the original donor phenotype and could thus improve the quality of patient care. An in vitro technique for the gen eration of RBCs with extremely rare phenotypes would be a major asset. Genetic manipulation of erythroid progenitor cell lines provides the possibility of developing on and off strategies to control the expression of blood group antigens and may be a first step toward using ex vivo genetically modified cells as tools for immunohematologic analysis in difficult transfusion situations. In addition, this genetic strategy could also be used to produce panels of genetically modified RBCs ex vivo that exhibit preselected phenotypes for clinical transfusion therapy of the final enucleated RBC product.
The current methodologies used to generate RBCs from either static or bioreactor suspension cultures exhaust the input HSCs ( figure 1b) . The large number of erythroid cells required means that existing bioreactor technologies are currently insufficient to meet the demands of routine RBC manufacture, and new breakthroughs in related technolo gies are needed. In contrast, the human body manufactures its RBCs in the bone marrow throughout an entire lifetime, using a contingent of HSCs that is maintained continuously in a delicate balance between selfrenewal and differentia tion, according to the body's requirements. Might we be able to replicate the HSC niche of the bone marrow in vitro to generate RBCs continuously? This result would require con ditions that support simultaneous erythropoiesis and main tenance of HSC stemness. This method would significantly reduce the cost of RBC manufacture because of the increased RBC production per input of HSCs and reductions in both medium volumes and dependence on expensive growth factors. Researchers have strived for decades to replicate the HSC niche ex vivo. How close are we to developing working blood farms for the production of RBCs? Although the con servation of HSC function in vitro has been an elusive target, several groups have recently shown increased maintenance of immature hematopoietic cells in an undifferentiated state when they are cultured in synthetic threedimensional (3D) scaffolds to mimic the architecture of the bone marrow niche (Shen and Nilsson 2012) . These 3D scaffolds are con structed of cancellous bone with osteoblasts differentiated from mesenchymal stem cells as support cells (Tan et al. 2010) , poly(D,Llactidecoglycolide) or polyurethane with collagen type I (MorteraBlanco et al. 2011), polyurethane foam with stromal support cells, and porous polyvinyl fluoride resin with support cells (Jozaki et al. 2010 , Miyoshi et al. 2011 . As yet, there is no clear consensus regarding the best scaffolding material, cellseeding density, or medium Overview Articles populations, are more suitable for discovering drugs for target diseases with variable clinical responses (Migliaccio G and Migliaccio AR 2010) . Ex vivo-expanded erythroid progenitor cells have recently been under consideration for use in in vitro assays aimed at identifying drugs for personalized therapy of diverse disorders, including induc ers of hemoglobin F production for thalassemia and sickle cell anemia, inhibitors of 11kDa nonstructural protein mediated caspase10 activation to prevent B19 parvovirus infection, and cellularbased antimalarial therapies (for a review, see Migliaccio AR et al. 2012a , 2012b .
Conclusions
These are exciting times in the field of stemcellderived erythrocyte research. Ex vivo-generated RBCs are needed to address specific needs in transfusion medicine. A major research effort is under way worldwide to refine methods for the in vitro expansion of RBCs with a view to their exploitation in a clinical setting. Here, we sought to view new perspectives and identify possible solutions to the problems associated with the clinical application of stem cellderived erythrocytes. Although these issues remain unsolved by the majority of protocols, it is exciting to note that we are already at the stage at which a proofofprinciple RBC product suitable for transfusion has been produced in a laboratory culture from adult peripheral blood stem cells. It seems likely that the first in vitro-produced transfu sion RBC product used therapeutically will be targeted at particular transfusion problems involving patients whose needs cannot be met by traditional transfusion products or patients with diseases for which ex vivo-expanded cells offer an improvement over traditional products. Aside from the needs of transfusion medicine, ex vivo-generated RBCs may have broader uses as drug delivery vehicles and in other specific circumstances. Although the expansion of abundant, enucleated, adultlike RBCs from human PSCs still presents a number of barriers, it is hoped that contin ued collaboration among clinical scientists, clinicians, and experts in transfusion medicine will allow the next decade to see significant advances in our understanding of the ex vivo generation of reagent RBCs and transfusion products. components such as osteoblasts and mesenchymal stem cells required to mimic the hematopoietic niche, but cellular components including megakaryocytes and macrophages are also needed and in their corresponding homeostatic fre quencies. Additional studies are therefore needed in order to replicate the complex HSC niche in vitro.
Stem-cell-derived RBCs: Potential for other clinical applications Although the underlying biology of RBC expansion and differentiation has yet to be fully addressed, achievements over the past decades are promising. RBCs, however, have additional clinical applications that do not pose a chal lenge in terms of the numbers of cells required. There are therefore some realistic intermediate therapeutic goals that could be achieved with the current technology. The clini cal applications that are within reach include drug delivery, drug discovery, and reagent RBCs for antibody identification (figure 1c).
RBCs are currently being considered as a vehicle for targeted drug delivery. Resealed RBCs, as a drug delivery system, have an excellent capacity to enhance the therapeutic index and to improve patient compliance, with great poten tial for achieving sitespecific drug delivery with minimal drug waste and prolonged drug release. Recent improve ments in retroviral technology have opened the possibility of using RBCs derived from genetically modified HSCs or HPCs as a vehicle for therapeutic recombinant proteins. Proof of principle for the use of RBCs for systemic protein delivery was obtained in mouse models of hemophilia, an Xlinked recessive congenital disorder of coagulation caused by coagulation factor VIII or IX deficiency. Hemophilia is currently treated with prophylactic factor infusion, which is expensive and requires high patient compliance (Chang AH et al. 2006) . It is possible that ex vivo-generated RBCs from molecularly engineered autologous CD34 + cells might represent a feasible option for achieving therapeutic levels of factor IX in hemophilia patients. Substantial progress in these intermediate clinical applications is likely to ensure that the ex vivo generation of RBC transfusion products will become a reality at some point in the future.
Advances in current technologies mean that in vitroexpanded RBCs could also be applied in drug discovery. In vitro tests using RBCs from donors with rare blood types are used to predict the suitability of these donors for alloimmunized patients. Because RBCs from rare donors are available in limited numbers, the generation of RBCs in vitro from mononuclear cells that are usually discarded during the leukoreduction process or from iPSCs derived from these cells may represent valuable substitutes for in vivo-generated reagent RBCs in these assays. In addition, preclinical toxicology and drug evaluation guidelines rec ommend reducing animal experimentation and increasing the sensitivity of preclinical toxicology and efficacy studies. In contrast to cell lines, primary cells, which could reflect age and sexrelated and genetic polymorphisms of human
